Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) traded down 1.7% during mid-day trading on Wednesday . The stock traded as low as $8.14 and last traded at $8.19. Approximately 1,235,305 shares changed hands during trading, an increase of 266% from the average daily volume of 337,931 shares. The stock had previously closed at $8.33.
Silverback Therapeutics Stock Down 1.7%
The stock has a market capitalization of $295.32 million, a P/E ratio of -3.38 and a beta of 0.60. The company has a 50 day moving average of $8.72 and a 200-day moving average of $9.23.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Read More
- Five stocks we like better than Silverback Therapeutics
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
